<br>From: <b class="gmail_sendername">Sama</b> <span dir="ltr"><<a href="mailto:sama.womenshealth@gmail.com">sama.womenshealth@gmail.com</a>></span><br>
<div class="gmail_quote"><span style="font-size:11pt;font-family:Calibri" lang="EN-GB"> </span><p class="MsoNormal"><span style="font-size:11pt;font-family:Calibri" lang="EN-GB">We would like to announce the release of the <b>report</b> on <b>‘The National Consultation on Regulation of Drug Trials.</b>” The Consultation held in 2011, was an effort towards initiating a dialogue around the </span><span style="font-size:11pt;font-family:Calibri" lang="EN-GB">existing
gaps in policy and its implementation vis-ŕ-vis the regulation of drug
trials, towards developing an appropriate framework for future int<a name="13664b05f84850fe_1365e1035e192176__GoBack" style="color:rgb(17,85,204)"></a>ervention strategies in this regard. The Consultation was organised by </span><span style="font-size:11pt;font-family:Calibri">Sama –Resource Group for Women and Health and others.</span><span style="font-size:11pt;font-family:Calibri" lang="EN-GB"></span></p>
<p class="MsoNormal"><span style="font-size:11pt;font-family:Calibri" lang="EN-GB"> </span></p><p class="MsoNormal"><span style="font-size:11pt;font-family:Calibri" lang="EN-GB">Recognising
the urgent need for furthering transparency in trials, protection of
participant rights, and implementation of the highest standards of
independent inquiry, this National-level Consultation was attended by
nearly 60 participants. It produced concrete recommendations for policy
and regulation on these issues.</span></p>
<p class="MsoNormal"><span style="font-size:11pt;font-family:Calibri" lang="EN-GB"> </span></p><p class="MsoNormal"><span style="font-size:11pt;font-family:Calibri" lang="EN-GB">Some
of the main themes that were discussed at the Consultation include –
The new division of labour in commercialised research; Regulatory
standards vis-ŕ-vis the conduct of clinical trials in India; Pressing
dilemmas and Issues with regard to the existing systems of regulation;
Issues of public health vis-ŕ-vis clinical trials; role of ethics
committees and Dilemmas in governance. While the concluding session,
facilitated a platform for collective strategizing over future
interventions towards people-centric clinical research. </span></p>
<p class="MsoNormal"><span style="font-size:11pt;font-family:Calibri" lang="EN-GB"> </span></p><p class="MsoNormal"><span style="font-size:11pt;font-family:Calibri">We would request, those of you who may be interested to write to us <b>directly</b> at </span><span lang="EN-GB"><a href="mailto:sama.womenshealth@gmail.com" style="color:rgb(17,85,204)" target="_blank"><span style="font-size:11pt;font-family:Calibri" lang="EN-US">sama.womenshealth@gmail.com</span></a></span><span style="font-size:11pt;font-family:Calibri"> for a copy. The Report is priced at US $3/- and an additional charge for postage.</span></p>
<p class="MsoNormal"><span style="font-size:11pt;font-family:Calibri"> </span></p><p class="MsoNormal"><span style="font-size:11pt;font-family:Calibri"> </span>website: <a href="http://www.samawomenshealth.org/" target="_blank">www.samawomenshealth.org</a> <br>
</p><span class="HOEnZb"><font color="#888888">Blog:<a href="http://samawomenshealth.wordpress.com/" target="_blank">http://samawomenshealth.wordpress.com/</a><br>
</font></span></div><br><br>